Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial

详细信息    查看全文

• 作者：Dr Gwenaelle Gravis ; MD^a ; ^{gravisg@ipc.unicancer.fr} ; Prof Karim Fizazi ; MD^c ; Prof Florence Joly ; MD^d ; Prof Sté ; phane Oudard ; MD^e ; Franck Priou ; MD^f ; Benjamin Esterni ; MSc^b ; Igor Latorzeff ; MD^g ; Remy Delva ; MD^h ; Prof Ivan Krakowski ; MDⁱ ; Brigitte Laguerre ; MD^j ; Fré ; deric Rolland ; MD^k ; Christine Thé ; odore ; MD^l ; Gael Deplanque ; MD^m ; Prof Jean Marc Ferrero ; MDⁿ ; Damien Pouessel ; MD^o ; Loï ; c Mourey ; MD^p ; Philippe Beuzeboc ; MD^q ; Sylvie Zanetta ; MD^r ; Muriel Habibian^s ; Jean Franç ; ois Berdah ; MD^t ; Jerome Dauba ; MD^u ; Marjorie Baciuchka ; MD^v ; Christian Platini ; MD^w ; Prof Claude Linassier ; MD^x ; Jean Luc Labourey ; MD^y ; Prof Jean Pascal Machiels ; MD^z ; Claude El Kouri ; MD^aa ; Prof Alain Ravaud ; MD^ab ; Etienne Suc ; MD^ac ; Jean Christophe Eymard ; MD^ad ; Ali Hasbini ; MD^ae ; Guilhem Bousquet ; MD^af ; Prof Michel Soulie ; MD^ag
• 刊名：Lancet Oncology
• 出版年：2013
• 出版时间：February, 2013
• 年：2013
• 卷：14
• 期：2
• 页码：149-158
• 全文大小：386 K

文摘

| Figures/TablesFigures/Tables | ReferencesReferences

Summary

Background

Early chemotherapy might improve the overall outcomes of patients with metastatic non-castrate (ie, hormone-sensitive) prostate cancer. We investigated the effects of the addition of docetaxel to androgen-deprivation therapy (ADT) for patients with metastatic non-castrate prostate cancer.

Methods

In this randomised, open-label, phase 3 study, we enrolled patients in 29 centres in France and one in Belgium. Eligible patients were older than 18 years and had histologically confirmed adenocarcinoma of the prostate and radiologically proven metastatic disease; a Karnofsky score of at least 70 % ; a life expectancy of at least 3 months; and adequate hepatic, haematological, and renal function. They were randomly assigned to receive to ADT (orchiectomy or luteinising hormone-releasing hormone agonists, alone or combined with non-steroidal antiandrogens) alone or in combination with docetaxel (75 mg/m² intravenously on the first day of each 21-day cycle; up to nine cycles). Patients were randomised in a 1:1 ratio, with dynamic minimisation to minimise imbalances in previous systemic treatment with ADT, chemotherapy for local disease or isolated rising concentration of serum prostate-specific antigen, and Glass risk groups. Patients, physicians, and data analysts were not masked to treatment allocation. The primary endpoint was overall survival. Efficacy analyses were done by intention to treat. This trial is registered with , number .

Findings

Between Oct 18, 2004, and Dec 31, 2008, 192 patients were randomly allocated to receive ADT plus docetaxel and 193 to receive ADT alone. Median follow-up was 50 months (IQR 39-63). Median overall survival was 58¡¤9 months (95 % CI 50¡¤8-69¡¤1) in the group given ADT plus docetaxel and 54¡¤2 months (42¡¤2-not reached) in that given ADT alone (hazard ratio 1¡¤01, 95 % CI 0¡¤75-1¡¤36). 72 serious adverse events were reported in the group given ADT plus docetaxel, of which the most frequent were neutropenia (40 [21 % ]), febrile neutropenia (six [3 % ]), abnormal liver function tests (three [2 % ]), and neutropenia with infection (two [1 % ]). Four treatment-related deaths occurred in the ADT plus docetaxel group (two of which were neutropenia-related), after which the data monitoring committee recommended treatment with granulocyte colony-stimulating factor. After this recommendation, no further treatment-related deaths occurred. No serious adverse events were reported in the ADT alone group.

Interpretation

Docetaxel should not be used as part of first-line treatment for patients with non-castrate metastatic prostate cancer.

Funding

French Health Ministry and Institut National du Cancer (PHRC), Sanofi-Aventis, AstraZeneca, and Amgen.